Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. (Nasdaq: IMNM) is a clinical-stage targeted oncology company whose news flow is closely tied to the progress of its cancer drug pipeline and capital markets activity. Press releases and updates frequently describe advances in its lead programs, including varegacestat, an investigational oral gamma secretase inhibitor for desmoid tumors, and IM-1021, a ROR1-targeted antibody-drug conjugate (ADC) that uses the company’s proprietary HC74 TOP1 inhibitor payload.
Investors following IMNM news can expect detailed announcements on clinical trial milestones, such as topline data from the global Phase 3 RINGSIDE trial of varegacestat, which met its primary and key secondary endpoints in patients with progressing desmoid tumors. Immunome also issues updates on early clinical activity for IM-1021 in B-cell lymphoma, IND clearance for the FAP-targeted radioligand IM-3050, and progress across its preclinical ADC programs IM-1617, IM-1335 and IM-1340.
In addition to R&D updates, Immunome regularly reports financial and corporate developments. Recent news includes quarterly financial results, guidance on cash runway, and details of a follow-on public offering of common stock under an effective shelf registration statement. The company also discloses inducement stock option grants under its 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), as well as participation in major healthcare and investor conferences.
This IMNM news page aggregates these disclosures so readers can track trial readouts, regulatory plans such as the intended NDA submission for varegacestat, financing transactions, and corporate presentations in one place. For investors, analysts and healthcare professionals, the stream of Immunome news provides insight into the evolution of its targeted oncology pipeline and its use of capital to support ongoing development.
Immunome (Nasdaq: IMNM) has announced the promotion of Max Rosett to Chief Financial Officer, effective May 9. Rosett, previously Executive Vice President of Operations and Interim CFO since January 2024, has played a key role in Immunome's recent strategic moves including the merger with Morphimmune and financial transactions worth over $350 million. CEO Clay Siegall emphasized Rosett's strategic insight and financial expertise as vital for advancing the company's pipeline, including the Phase 3 RINGSIDE trial of AL102 and preparing IM-1021 and IM-3050 for IND submission. Rosett's background includes senior roles at Morphimmune and experience at Research Bridge Partners, Google, and Boston Consulting Group.
Immunome (Nasdaq: IMNM), a biotech company focused on targeted cancer therapies, reported its Q1 2024 financial results and provided a business update. The company has integrated AL102 and IM-1021 and is progressing towards regulatory submissions. Topline data for the Phase 3 RINGSIDE trial of AL102 is expected in H2 2025. IND submissions for IM-1021 and IM-3050 are anticipated in Q1 2025. Financially, Immunome has $309.7 million in cash and equivalents, with a runway extending into 2026. Q1 2024 expenses included $15.4 million in R&D, $112 million in in-process R&D from recent acquisitions, and $6 million in administrative costs. The company posted a net loss of $129.5 million, or $2.51 per share.
Immunome, Inc. (IMNM) will be presenting at the 2024 Bank of America Healthcare Conference. The President and CEO, Clay Siegall, will present on May 15, 2024. Interested parties can access the live webcast on the company's website.
Immunome, Inc. (Nasdaq: IMNM) has appointed Kinney Horn as Chief Business Officer, bringing extensive experience in life sciences corporate and business development to the company. With the recent acquisition of AL102, Immunome is now a clinical stage company, aiming to enhance its development capabilities and expand its portfolio of targeted cancer therapies. Mr. Horn's successful track record in strategic partnerships will play a important role in Immunome's growth.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.